McLeod L, Ervin C, Fehnel SE, Eremenco S, Carson RT, Hanlon J, Coons SJ. Psychometric evaluation of the diary for irritable bowel syndrome symptoms-constipation in a prospective observational study. Value Health. 2024 May;27(5):614-22. doi: 10.1016/j.jval.2024.01.013
Cotter SP, Schwartz L, Strong TV, Bender RH, Fehnel S. The Prader-Willi syndrome anxiousness and distress behaviors questionnaire: development and psychometric validation. Value Health. 2023 Feb 1;26(2):243-50. doi: 10.1016/j.jval.2022.08.004
Fehnel SE, Ervin CM, Carson RT, Rigoni G, Lackner JM, Coons SJ. Development of the diary for irritable bowel syndrome symptoms to assess treatment benefit in clinical trials: foundational qualitative research. Value Health. 2017 Apr;20(4):618-26.
Forsyth B, Fehnel SE, Danchenko N, Franois C, Brevig T. Assessing impacts of major depressive disorder (MDD) on cognitive function. Value Health. 2012 Nov 1;15(7):A341.
Brown TM, Olanrewaju B, Deal L, Katz EC, Chiou C, Martin S, Fehnel S. Assessing pruritus among patients with atopic dermatitis: targeted literature and instrument review. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 6, 2012. [abstract] Value Health. 2012 Jun; 15(4):A253.
DeMuro C, Clark M, Mordin M, Fehnel S, Copley-Merriman C, Gnanasakthy A. Reasons for rejection of patient-reported outcome label claims: a compilation based on a review of patient-reported outcome use among new molecular entities and niologic license applications, 2006-2010. Value Health. 2012 May 1;15(3):443-8.
Gnanasakthy A, Mordin M, Clark M, DeMuro C, Fehnel S, Copley-Merriman C. A review of patient-reported outcome labels in the United States: 2006 to 2010. Value Health. 2012 May;15(3):437-42. doi: 10.1016/j.jval.2011.11.032
Mordin M, Clark M, DeMuro C, Evans ED, Copley-Merriman K, Fehnel S, Gnanasakthy A. Pro label claims: an analysis based on a review of pros among new molecular entities and biologic license applications 2006-2010. Poster presented at the 2011 ISPOR 16th Annual International Meeting; June 3, 2011. [abstract] Value Health. 2011 May; 14(3):A29.
DeMuro C, Mordin M, Evans ED, Copley-Merriman K, Fehnel S, Gnanasakthy A. Reasons for rejection of PRO label claims: an analysis based on a review of PRO use among new molecular entities and biologic license applications 2006–2010. Poster presented at the 2011 ISPOR 16th Annual International Meeting; June 3, 2011. [abstract] Value Health. 2011 May; 14(3):A29.
Fehnel S, Ervin CM, Lewis B, Carson RT, Johnston JM. Identifying endpoints for irritable bowel syndrome (IBS) clinical trials: incorporating the patient's voice. Poster presented at the 2010 ISPOR 13th Annual European Congress; November 15, 2010. [abstract] Value Health. 2010 Nov; 13(7):A372.
Ervin CM, Fehnel S, Carson R, Kurtz C, Shiff S, Johnston J. Selecting chronic constipation (CC) clinical trial endpoints: incorporating the patient's voice. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 28, 2010. [abstract] Value Health. 2010 May; 13(3):A74.
Mordin MM, Lewis SA, Gnanasakthy A, DeMuro-Mercon CJ, Copley-Merriman K, Fehnel SE. Patient-reported outcomes in product development guidance. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 1, 2010. Atlanta, GA. [abstract] Value Health. 2010 May; 13(3):A-17-8.
Mordin M, Lewis SE, Gnanasakthy A, Demuro-Mercon C, Copley-Merriman K, Fehnel S. Patient-reported outcomes as mentioned in product development guidance. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 4, 2010. [abstract] Value Health. 2010 May; 13(3):A17-8.
Fehnel S. Establishing optimal requirements for content validity: a work in progress. Value Health. 2009 Nov 1;12(8):1074.
McLeod LD, Fehnel SE, Zografos LJ, Sander SD, Curtis TG, Shah H. The impact of restless legs syndrome on various dimensions of life: results of a web-based patient survey. Poster presented at the 2007 ISPOR 12th Annual International Meeting; May 22, 2007. [abstract] Value Health. 2007 May; 10(3):A95.
Williams VSL, Fehnel SE, Hollis KA, Hogue SL. Antidepressant-induced sexual dysfunction (ADSD) in Europe: a preliminary investigation. Poster presented at the 2004 ISPOR 9th Annual International Meeting; May 16, 2004. Arlington, VA. [abstract] Value Health. 2004 May; 7(4):361-2.
Eaton SC, Cook SF, Andrews EB, Hollis KA, Ameen VZ, Fehnel SE. Using a web-panel to aid definition of a target patient population to assist risk management. Value Health. 2004 May 1;7(3):309.
Eaton SC, Cook SF, Andrews EB, Hollis KA, Ameen VZ, Mangel AW, Fehnel S. Using a web panel to aid definition of a target population to assist risk management. Poster presented at the 2004 ISPOR 9th Annual International Meeting; May 16, 2004. Arlington, VA. [abstract] Value Health. 2004 May; 7(3):309.
Wincze J, Fehnel SE, McLeod LD, Granger AL, Merchant S. Development and initial testing of a new patient-reported questionnaire: erection quality scale. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research Sixth Annual European Congress; November 1, 2003. Barcelona, Spain. [abstract] Value Health. 2003 Nov; 6(6):709.
Wincze JP, Fehnel SE, McLeod LD, Granger AL, Merchant S. Development and initial testing of a new patient-reported questionnaire-erection quality scale. Value Health. 2003 Jan 1;6(6):709.